The cost-effectiveness of radon-proof membranes in new homes: A case study from Brixworth, Northamptonshire, UK

Health Policy

Volumn 81, Issue 2-3, 2007, Pages 195-206

  Coskeran, Thomas ^a   Denman, Antony ^b   Phillips, Paul ^c   Tornberg, Roger ^d  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^b NORTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF NORTHAMPTON   (United Kingdom)

^d Radon Centres Ltd   (United Kingdom)

Author keywords

Cost effectiveness analysis; Lung cancer; Membranes; Radon remediation

Indexed keywords

RADON;

ARTICLE; COST EFFECTIVENESS ANALYSIS; HOME ENVIRONMENT; HOME MONITORING; HOUSING; HUMAN; LUNG CANCER; MEMBRANE; QUALITY ADJUSTED LIFE YEAR; RADIATION EXPOSURE; RADIATION PROTECTION; UNITED KINGDOM;

COST-BENEFIT ANALYSIS; ENGLAND; ENVIRONMENTAL EXPOSURE; FACILITY DESIGN AND CONSTRUCTION; HOUSING; HUMANS; RADON;

EID: 33947431677     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2006.06.005     Document Type: Article

References (55)

1. Hughes JS. Ionising Radiation Exposure of the UK Population: 1999 Review. Report R311, National Radiological Protection Board Report. Chilton, UK: NRPB.
2. Lubin J., and Boice J.D. Lung cancer risk from residential radon: a meta-analysis of eight epidemiological studies. Journal of the National Cancer Institute 89 1 (1997) 49-57
3. Denman A.R., and Phillips P.S. A review of the cost effectiveness of radon mitigation in domestic properties in Northamptonshire. Journal of Radiology Protection 18 (1998) 119-124
4. Darby S., Whitley E., Silcocks P., Thakrar B., Green M., Lomas P., et al. Risk of lung lancer associated with residential radon exposure in South-West England: a case-control study. British Journal of Cancer 78 (1998) 394-408
5. Kreienbrock L., Kreuzer M., Gerken M., Dingerkus G., Wellmann J., Keller G., et al. Case-control study on lung-cancer and residential radon in Western Germany. American Journal of Epidemiology 153 (2001) 42-52
6. Darby S., Hill R., and Doll R. Radon: a likely carcinogen at all exposures. Annals of Oncology 12 10 (2001) 1341-1351
7. Darby S., Hill D., Auvinen A., Barros-Dios J.M., Baysson H., Bochicchio F., et al. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. BMJ 330 (2005) 223-228
8. Krewski D., Lubin J.H., Zielinski J.M., Alavanja M., Catalan V.S., William F.R., et al. Residential radon and risk of lung cancer: a combined analysis of 7 North American case-control studies. Epidemiology 16 (2005) 137-145
9. O'Riordan M. Human exposure to radon in homes: recommendations for the practical application of the Board's statement. Documents of the NRPB, Chilton, UK 1 1 (1990) 17-32
10. National Radiological Protection Board. Estimates of late radiation risk to the UK population. Documents of the NRPB 4 (4) (1993), National Radiological Protection Board, Chilton, UK
11. Building Research Establishment (BRE). Radon: Guidance on Protective Measures for New Dwellings. BRE Report BR211 1992. Watford, UK.
12. Building Research Establishment (BRE). Radon: Guidance on Protective Measures for New Dwellings 1999 Edition. BRE Report BR211 1999. Watford, UK.
13. Denman A.R., Phillips P.S., and Tornberg R. A comparison of the costs and benefits of radon remediation programmes in new and existing houses in Northamptonshire. Journal of Environmental Management 59 (2000) 21-30
14. Kennedy C.A., Gray A.M., Denman A.R., and Phillips P.S. A cost effectiveness analysis of a residential radon remediation programme in the United Kingdom. British Journal of Cancer 81 (1999) 1243-1247
15. Coskeran T., Denman A., and Phillips P. The cost of radon remediation in domestic properties. Health Policy 57 2 (2001) 97-109
16. Coskeran T., Denman A.R., Phillips P.S., and Gillmore G. A critical comparison of the cost-effectiveness of domestic radon remediation programmes in three counties of England. Journal of Environmental Radioactivity 62 (2002) 129-144
17. Stigum H., Strand T., and Magnus P. Should radon be reduced in homes? A cost-effectiveness analysis. Health Physics 84 2 (2003) 227-235
18. Coskeran T., Denman A.R., Phillips P.S., and Tornberg R. A cost-effectiveness analysis of domestic radon remediation in four primary care trusts located in Northamptonshire, UK. Health Policy 71 1 (2005) 43-56
19. Denman A.R., Phillips P.S., Groves-Kirkby C.J., and Crockett R.G.M. Do radon-proof membranes reduce radon levels adequately in new houses?. Proceedings of the Seventh SRP International Symposium. Cardiff, 12-17 June (2005). http://www.srp-uk.org/cardiff05proc.pdf available at http://www.srp-uk.org/cardiff05proc.pdf
20. Groves-Kirkby C.J., Denman A.R., Phillips P.S., Crockett R.G.M., Woolridge A.C., and Tornberg R. Radon mitigation in domestic properties and its health implications-a comparison between during-construction and post-construction radon reduction. Environment International 32 (2006) 435-443
21. Green BMR, Miles JCH, Bradley EJ, Rees DM. Radon Atlas of England and Wales. National Radiological Protection Board Report W26, Didcot, UK, 2002.
22. Sundal A.V., Henriksen H., Soldal O., and Strand T. The influence of geological factors on indoor concentrations of radon in Norway. Science of the Total Environment 328 (2004) 41-53
23. Sutherland D., and Sharman G. Radon-in Northamptonshire?. Geology Today 12 2 (1996) 63
24. Office for the Deputy Prime Minister. Sustainable communities: building for the future (the sustainable communities plan) (2003), The Stationery Office, London, UK
25. Wrixon AD, Green BMR, Lomas PR, Miles JCH, Cliff KD, Francis EA, et al. Natural radiation exposure in UK dwellings Report NRPB-R190. National Radiological Protection Board, Didcot, UK, 1988.
26. Pinel J., Fearn T., Darby S.C., and Miles J.C.H. Seasonal correction factors for indoor radon measurements in the United Kingdom. Radiation Protection Dosimetry 58 (1995) 127-132
27. Briggs D.J., Denman A.R., Gulliver J., Marley R.F., Kennedy C.A., Phillips P.S., et al. Time-activity modelling of domestic exposures to radon. Journal of Environmental Management 67 2 (2003) 107-120
28. Miles J.C.H., and Mapping. Radon-prone areas by lognormal modeling of house radon data. Health Physics 74 3 (1998) 270-278
29. Coskeran T., Denman A.R., Phillips P.S., and Tornberg R. A new methodology for cost-effectiveness studies of domestic radon remediation programmes: quality-adjusted life-years gained within Primary Care Trusts in Central England. Science of the Total Environment 366 (2006) 32-46
30. Trippoli S., Vaiani M., Lucioni C., and Messori A. Quality of life and utility in patients with non-small cell lung cancer. Pharmacoeconomics 19 8 (2001) 855-863
31. Clegg A., Scott D.A., Sidhu M., Hewitson P., and Waugh N. Clinical and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer: a systematic review. Thorax 57 1 (2002) 20-28
32. Denman A.R., Eatough J.P., Gillmore G., and Phillips P.S. Assessment of health risks to skin and lung from elevated levels in abandoned mines. Health Physics 85 6 (2003) 733-739
33. Warner K.E., Courant P.N., and Mendez D. Effects of residential mobility on individual versus population risk of radon-related lung cancer. Environmental Health Perspectives 103 12 (1995) 1144-1149
34. Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. Cost-effectiveness in health and medicine (1996), Oxford University Press, Oxford, UK
35. Her Majesty's Treasury. The green book: appraisal and evaluation in central government (2003), The Stationery Office, London, UK 114 p
36. Colgan P.A., and Gutierrez J. Justification and optimisation in the choice of reference levels for radon in existing Spanish dwellings. Journal of Radiological Protection 15 (1995) 289-301
37. Kennedy C.A., Gray A.M., Denman A.R., and Phillips P.S. The cost-effectiveness of residential radon remediation programmes: assumptions about benefits stream profiles over time. Journal of Environmental Radioactivity 59 (2002) 19-28
38. Committee on Health Risks of Exposure to Radon (BEIR VI). Health effects of exposure to radon (1999), National Academic Press, Washington, DC
39. Stephens M.A. EDF statistics for goodness of fit and some comparisons. Journal of the American Statistical Association 69 (1974) 730-737
40. Mason J., Drummond M., and Torrance G. Some guidelines on the use of cost-effectiveness league tables. British Medical Journal 306 6877 (1993) 570-572
41. Scuffman P.A., and Chaplin S. An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK. Pharmacoeconomics 22 8 (2004) 525-535
42. Fiscella K., and Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. Journal of the American Medical Association 275 16 (1996) 1247-1251
43. Barr R., Feeny D., and Furlong W. Economic evaluation of treatments for cancer in childhood. European Journal of Cancer 40 9 (2004) 1335-1345
44. Coskeran T., Denman A.R., Phillips P.S., and Tornberg R. The cost per quality adjusted life year gained of domestic radon remediation in four Northamptonshire Primary Care Trusts. Proceedings of the Seventh SRP International Symposium. Cardiff, UK, 12-17 June (2005). http://www.srp-uk.org/cardiff05proc.pdf available at
45. Marshall D., Simpson K.N., Earle C.C., and Chu C.-W. Economic decision analysis model of screening for lung cancer. European Journal of Cancer 37 (2001) 1759-1767
46. Health Technology Assessment. The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review, vol. 5, no. 13, 2001, 73 p.
47. Health Technology Assessment. The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review, vol. 5, no. 2, 2001, 97 p.
48. Allsup S., Haycox A., Regan M., and Gosney M. Is influenza vaccination cost effective for healthy people between ages 65 and 74 years? A randomised controlled trial. Vaccine 23 5 (2004) 639-645
49. Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. British Medical Journal 323 (2001) 1300-1303
50. Williams A., What could be nicer than NICE? Office of Health Economics Annual Lecture; 2004.
51. Baker R, Chilton S, Donaldson C, Jones-Lee M, Metcalf H, Shackley P, et al. Determining the Societal Value of a QALY by Surveying the Public in England and Wales: A Research Protocol. Submission to National Institute for Clinical Excellence and National Coordinating Centre for Research Methodology; 2003.
52. Kip Viscusi W. The value of risks to life and health. Journal of Economic Literature 31 4 (1993) 1912-1946
53. Ferrer-i-Carbonell A., and van Praag B. The subjective costs of health losses due to chronic diseases: an alternative model for monetary appraisal. Health Economics 11 (2002) 709-722
54. Hirth R.A., Chernew M.E., Miller E., Fendrick A.M., and Weissert W.G. Willingness to pay for a quality-adjusted life year: in search of a standard. Medical Decision Making 20 (2000) 332-342
55. Gyrd-Hansen D. Willingness to pay for a QALY. Health Economics 12 12 (2003) 1049-1060